argenex (NASDAQ:ARGX) Shares Bought by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of argenex SE (NASDAQ:ARGX). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $15,001 and $50,000 in argenex stock on October 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

argenex Stock Up 0.4%

NASDAQ:ARGX traded up $3.75 during trading hours on Thursday, reaching $981.33. The company had a trading volume of 449,412 shares, compared to its average volume of 423,265. The stock has a 50-day moving average of $925.74 and a two-hundred day moving average of $860.30. argenex SE has a one year low of $661.85 and a one year high of $1,072.75. The firm has a market capitalization of $61.72 billion, a PE ratio of 34.24, a PEG ratio of 0.91 and a beta of 0.48.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion during the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. As a group, sell-side analysts expect that argenex SE will post 28.41 earnings per share for the current year.

Hedge Funds Weigh In On argenex

Institutional investors and hedge funds have recently bought and sold shares of the business. Eastern Bank bought a new stake in argenex during the 2nd quarter worth about $32,000. Harbour Investments Inc. raised its stake in shares of argenex by 966.7% in the third quarter. Harbour Investments Inc. now owns 64 shares of the company’s stock worth $62,000 after acquiring an additional 58 shares during the last quarter. Axiom Investment Management LLC bought a new position in shares of argenex in the first quarter worth about $50,000. Richardson Financial Services Inc. acquired a new position in shares of argenex during the third quarter worth approximately $66,000. Finally, Bogart Wealth LLC lifted its position in shares of argenex by 2,500.0% during the third quarter. Bogart Wealth LLC now owns 78 shares of the company’s stock worth $75,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on ARGX. Barclays restated a “buy” rating on shares of argenex in a research note on Monday, September 7th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of argenex in a research report on Wednesday, August 5th. Oppenheimer cut their price target on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a report on Monday, October 12th. Robert W. Baird boosted their price target on shares of argenex from $823.00 to $861.00 and gave the company a “neutral” rating in a research report on Friday, October 23rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of argenex in a research note on Monday, September 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and an average price target of $1,158.76.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

argenex Company Profile

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.